<DOC>
	<DOCNO>NCT00952341</DOCNO>
	<brief_summary>This study demonstrate confirm efficacy safety MK0869 treatment chemotherapy-induced nausea vomit Chinese patient .</brief_summary>
	<brief_title>Aprepitant/MK0869 Prevention Chemotherapy Induced Nausea Vomiting Associated With Cisplatin ( 0869-169 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Cycle 1 : Patient schedule receive his/her first course cisplatin chemotherapy dose least 70 mg/m^2 administer maximum 3 hour Patient predict life expectancy least 3 month Patient pregnant Cycle 2 ( optional ) : Participation study next cycle chemotherapy consider appropriate investigator pose unwarranted risk patient . Satisfactory completion precede cycle chemotherapy relate study procedure . Patient continue receive chemotherapy regimen Cycle 1 . The cisplatin dose may reduce subsequent cycle , long new dose still less 70 mg/m^2 . Cycles 1 &amp; 2 : Patient receive stem cell therapy conjunction cisplatin Patient active infection uncontrolled disease ( e.g . diabetes ) Patient receive multipleday chemotherapy cisplatin Patient receive chemotherapy moderate high emetogenicity 6 day prior cisplatin infusion 6 day follow cisplatin infusion Patient vomit within 24 hour prior cisplatin infusion Patient receive receive radiation therapy abdomen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>CINV</keyword>
</DOC>